Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
Danaher delivered modest FY2025 recovery: .6B revenue (+3.0%), adj. EPS .80 (+4.5%), FCF .3B. Bioprocessing strengthening but Life Sciences segment profit collapsed 57%. Pending Masimo acquisition add...